AstraZeneca has entered an exclusive licensing agreement with CSPC Pharmaceutical to advance the development of YS2302018, an early-stage oral Lipoprotein (a) disruptor. This novel small molecule has the potential to treat dyslipidaemia and other cardiovascular conditions, enhancing AstraZeneca's growing cardiovascular portfolio. The agreement reflects both companies' commitment to addressing chronic cardiovascular disease, a leading global health issue.
YS2302018, discovered by CSPC, targets Lipoprotein (a) (Lp(a)), a form of low-density lipoprotein associated with increased cardiovascular risks, including coronary artery disease and stroke. Elevated Lp(a) levels contribute to poor cardiovascular outcomes, making it a critical target for treatment. AstraZeneca aims to explore the drug’s potential both as a standalone therapy and in combination with other lipid-lowering agents, like the PCSK9 inhibitor AZD0780.
Under the agreement, CSPC will receive an upfront payment of $100 million from AstraZeneca, with the potential for an additional $1.92 billion in development milestones and tiered royalties. The collaboration aims to accelerate the development of YS2302018, providing an innovative approach to managing dyslipidaemia and other cardiometabolic diseases.
Click here to read the original news story.